Robert Gaffin

Robert Gaffin

Auto-generated profile, based on publicly available information

Robert Gaffin

Cardiovascular Metabolism Program, Sanford Burnham Prebys Medical Discovery Institute at Lake Nona, Orlando, FL 32827, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2017 in Science Signaling
Verified
Journal Article
Closed access
PDF file
WWWei Wu
Wei Wu
FSFubiao Shi
Fubiao Shi
DLDianxin Liu
Dianxin Liu
RCRyan P. Ceddia
Ryan P. Ceddia
RGRobert Gaffin
Robert Gaffin
SCSheila Collins
Sheila Collins
In addition to controlling blood pressure, cardiac natriuretic peptides (NPs) can stimulate lipolysis in adipocytes and promote the “browning” of white adipose tissue. NPs may also increase the oxidative capacity of skeletal muscle. To unravel the contribution of NP-stimulated metabolism in adipose tissue compared to that in muscle in vivo, we generated mice with tissue-specific deletion of the NP clearance receptor, NPRC, in adipose tissue (NprcAKO) or in skeletal muscle (NprcMKO). We showed that, similar to Nprc null mice, NprcAKO mice, but not NprcMKO mice, were resistant to obesity induced by a high-fat diet. NprcAKO mice exhibited increased energy expenditure, improved insulin sensitivity, and increased glucose uptake into brown fat. These mice were also protected from diet-induced hepatic steatosis and visceral fat inflammation. These findings support the conclusion that NPRC in adipose tissue is a critical regulator of energy metabolism and suggest that inhibiting this receptor may be an important avenue to explore for combating metabolic disease.

22 April 2014 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
JWJ. Ruth Wu‐Wong
J. Ruth Wu‐Wong
YCYung‐Wu Chen
Yung‐Wu Chen
RGRobert Gaffin
Robert Gaffin
AHAndy Hall
Andy Hall
JWJonathan T. Wong
Jonathan T. Wong
JWJerry L. Wessale
Jerry L. Wessale
Inadequate control of serum phosphate in chronic kidney disease can lead to pathologies of clinical importance. Effectiveness of on‐market phosphate binders is limited by safety concerns and low compliance due to high pill size/burden and gastrointestinal (GI) discomfort. VS‐501 is a nonabsorbed, calcium‐ and aluminum‐free, chemically modified, plant‐derived polymer. In vitro studies show that VS‐501 has a high density and a low swell volume when exposed to simulated gastric fluid (vs. sevelamer). When male Sprague–Dawley (SD) rats on normal diet were treated with VS‐501 or sevelamer, serum phosphate was not significantly altered, but urinary phosphate levels decreased by >90%. VS‐501 had no effect on serum calcium (Ca) or urinary Ca, while 3% sevelamer significantly increased serum and urine Ca. In 5/6 nephrectomized (NX) uremic SD rats on high‐phosphate diet, increasing dietary phosphate led to an increase in serum and urine phosphate, which was prevented in rats treated with VS‐501 or sevelamer (0.2–5% in food). High‐phosphate diet also increased serum fibroblast growth factor‐23 and parathyroid hormone in 5/6 NX rats that was prevented by VS‐501 or sevelamer. VS‐501 or sevelamer increased fecal phosphate in a dose‐dependent manner. More aortic calcification was observed in 5/6 NX rats treated with 5% sevelamer, while VS‐501 and sevelamer did not show significant effects on cardiac parameters, fibrosis, intestine histology, and intestinal sodium‐dependent phosphate cotransporter gene expression. These results suggest that VS‐501 is effective in binding phosphate with no effects on calcium homeostasis, and may have improved pill burden and GI side effects.